Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseasePaul M. Ridker, Robert J. Glynn, Tom Thurén et al.|New England Journal of Medicine|2017Cited by 9.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionJohn J.V. McMurray, Anna-Maria Langkilde, Morten Schou et al.|New England Journal of Medicine|2019Cited by 6.8k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial InfarctionMarc P. Bonaca, Marc S. Sabatine, Deepak L. Bhatt et al.|New England Journal of Medicine|2015Cited by 2k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialPaul M. Ridker, Hakan Kültürsay, Jean MacFadyen et al.|The Lancet|2017Cited by 1.3k
Vorapaxar in the Secondary Prevention of Atherothrombotic EventsDavid A. Morrow, Sabina A. Murphy, Eugene Braunwald et al.|New England Journal of Medicine|2012Cited by 941